TY - JOUR
T1 - Expectant treatment with curative intent in the prostate-specific antigen era
T2 - Triggers for definitive therapy
AU - Warlick, Christopher A.
AU - Allaf, Mohamad E.
AU - Carter, H. Ballentine
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2006/1
Y1 - 2006/1
N2 - Expectant treatment with curative intent for treatment of low-risk prostate cancer faces 3 challenges in the PSA era: (1) appropriate patient selection, (2) adequate surveillance strategies, and (3) identification of triggers for definitive intervention when cure is still possible. Men 65 years or older with T1c disease, prostate-specific antigen density <0.15 ng/ml/cm3, and favorable biopsy characteristics per the Epstein criteria currently appear to be the safest candidates for expectant treatment. Changes in biopsy characteristics are the most objective trigger for definitive therapy currently in use. Outcomes data are still required to determine the safety of expectant treatment for localized disease.
AB - Expectant treatment with curative intent for treatment of low-risk prostate cancer faces 3 challenges in the PSA era: (1) appropriate patient selection, (2) adequate surveillance strategies, and (3) identification of triggers for definitive intervention when cure is still possible. Men 65 years or older with T1c disease, prostate-specific antigen density <0.15 ng/ml/cm3, and favorable biopsy characteristics per the Epstein criteria currently appear to be the safest candidates for expectant treatment. Changes in biopsy characteristics are the most objective trigger for definitive therapy currently in use. Outcomes data are still required to determine the safety of expectant treatment for localized disease.
KW - Curative intervention
KW - Expectant management
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=30744453538&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=30744453538&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2005.07.004
DO - 10.1016/j.urolonc.2005.07.004
M3 - Article
C2 - 16414495
AN - SCOPUS:30744453538
SN - 1078-1439
VL - 24
SP - 51
EP - 57
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 1
ER -
